EAST HANOVER, N.J., June 16, 2020 /PRNewswire/ — Novartis, a leader in rheumatology and immuno-dermatology, today announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of active…Original Article
Cosentyx Receives FDA Approval for New Indication to Treat Active Non-Radiographic Axial Spondyloarthritis
